A previous systematic review of the efficacy and toxicity in patients with EGFR-mutated NSCLC had shown that combined inhibition of the EGFR and VEGF pathways significantly increased any grade 3–4 toxicity compared to EGFR inhibition alone (57). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.